• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类囊泡单胺转运体2(VMAT2)的药物抑制作用及底物转运机制

Drug inhibition and substrate transport mechanisms of human VMAT2.

作者信息

Wei Feiwen, Liu Huihui, Zhang Wei, Wang Jufang, Zhang Yanqing

机构信息

Shanghai Fifth People's Hospital, Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai, China.

Arieh Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, China.

出版信息

Nat Commun. 2025 Jan 2;16(1):323. doi: 10.1038/s41467-024-55361-0.

DOI:10.1038/s41467-024-55361-0
PMID:39747030
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11695631/
Abstract

Vesicular monoamine transporter 2 (VMAT2) is crucial for packaging monoamine neurotransmitters into synaptic vesicles, with their dysregulation linked to schizophrenia, mood disorders, and Parkinson's disease. Tetrabenazine (TBZ) and valbenazine (VBZ), both FDA-approved VMAT2 inhibitors, are employed to treat chorea and tardive dyskinesia (TD). Our study presents the structures of VMAT2 bound to substrates serotonin (5-HT) and dopamine (DA), as well as the inhibitors TBZ and VBZ. Utilizing cryo-electron microscopy (cryo-EM), mutagenesis functional assays, and molecular dynamics (MD) simulations, we elucidate the mechanisms of substrate transport and drug inhibition. Our MD simulations indicate potential binding poses of substrate (5-HT) in both cytosol-facing and lumen-facing states, emphasizing the significance of protonation of key acidic residues for substrate release. We demonstrate that TBZ locks VMAT2 in a lumen-facing occluded state, while VBZ stabilizes it in a lumen-facing conformation. These insights enhance our understanding of VMAT2 function and provide valuable insights for the development of novel therapeutic strategies for psychiatric disorders.

摘要

囊泡单胺转运体2(VMAT2)对于将单胺类神经递质包装到突触小泡中至关重要,其功能失调与精神分裂症、情绪障碍和帕金森病有关。丁苯那嗪(TBZ)和缬苯那嗪(VBZ)均为美国食品药品监督管理局(FDA)批准的VMAT2抑制剂,用于治疗舞蹈症和迟发性运动障碍(TD)。我们的研究展示了与底物血清素(5-HT)、多巴胺(DA)以及抑制剂TBZ和VBZ结合的VMAT2的结构。利用冷冻电子显微镜(cryo-EM)、诱变功能测定和分子动力学(MD)模拟,我们阐明了底物转运和药物抑制的机制。我们的MD模拟表明了底物(5-HT)在面向胞质溶胶状态和面向内腔状态下的潜在结合姿势,强调了关键酸性残基质子化对于底物释放的重要性。我们证明TBZ将VMAT2锁定在面向内腔的封闭状态,而VBZ使其稳定在面向内腔的构象。这些见解加深了我们对VMAT2功能的理解,并为精神疾病新型治疗策略的开发提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/b2d878c85261/41467_2024_55361_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/247d8bc6f88a/41467_2024_55361_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/d3c58ad7421b/41467_2024_55361_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/4a6d9a1df656/41467_2024_55361_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/b2d878c85261/41467_2024_55361_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/247d8bc6f88a/41467_2024_55361_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/d3c58ad7421b/41467_2024_55361_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/4a6d9a1df656/41467_2024_55361_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da7e/11695631/b2d878c85261/41467_2024_55361_Fig4_HTML.jpg

相似文献

1
Drug inhibition and substrate transport mechanisms of human VMAT2.人类囊泡单胺转运体2(VMAT2)的药物抑制作用及底物转运机制
Nat Commun. 2025 Jan 2;16(1):323. doi: 10.1038/s41467-024-55361-0.
2
Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders.小儿多动性运动障碍中VMAT2抑制剂的真实世界经验
Tremor Other Hyperkinet Mov (N Y). 2025 Jun 16;15:26. doi: 10.5334/tohm.1023. eCollection 2025.
3
Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.比较研究二氢苯丁氮酮和戊苯那嗪作为 VMAT2 抑制剂治疗迟发性运动障碍的疗效:系统综述。
Tremor Other Hyperkinet Mov (N Y). 2024 Mar 13;14:13. doi: 10.5334/tohm.842. eCollection 2024.
4
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.VMAT-2抑制剂治疗迟发性运动障碍:随机对照试验的系统评价和荟萃分析
Drug Des Devel Ther. 2018 May 14;12:1215-1238. doi: 10.2147/DDDT.S133205. eCollection 2018.
5
Transport and inhibition mechanisms of human VMAT2.人 VMAT2 的转运和抑制机制。
Nature. 2024 Feb;626(7998):427-434. doi: 10.1038/s41586-023-06926-4. Epub 2023 Dec 11.
6
Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.人 VMAT2 中神经递质转运和药物抑制的机制。
Nature. 2023 Nov;623(7989):1086-1092. doi: 10.1038/s41586-023-06727-9. Epub 2023 Nov 1.
7
Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.VMAT2 介导的单胺类突触囊泡摄取的转运和抑制机制。
Cell Res. 2024 Jan;34(1):47-57. doi: 10.1038/s41422-023-00906-z. Epub 2024 Jan 2.
8
Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?用于迟发性运动障碍的氘代丁苯那嗪:对这种新批准的新型药物的疗效和安全性概况的系统评价——治疗所需人数、伤害所需人数以及受益或受害可能性是多少?
Int J Clin Pract. 2017 Jul;71(7). doi: 10.1111/ijcp.12964. Epub 2017 May 12.
9
Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?用于迟发性运动障碍的氘代丁苯那嗪:对这种新批准的新型药物的疗效和安全性概况的系统评价——治疗所需人数、伤害所需人数以及受益或受害可能性是多少?
Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13030. Epub 2017 Oct 12.
10
Structural mechanisms for VMAT2 inhibition by tetrabenazine.四苯嗪抑制 VMAT2 的结构机制。
Elife. 2024 Mar 22;12:RP91973. doi: 10.7554/eLife.91973.

引用本文的文献

1
Predictive Value of Perivascular Space Network and Choroid Plexus for Levodopa Responsiveness in Parkinson's Disease.帕金森病中血管周围间隙网络和脉络丛对左旋多巴反应性的预测价值
Eur J Neurol. 2025 Jul;32(7):e70290. doi: 10.1111/ene.70290.

本文引用的文献

1
Neurotransmitter recognition by human vesicular monoamine transporter 2.人囊泡单胺转运体2对神经递质的识别
Nat Commun. 2024 Sep 16;15(1):7661. doi: 10.1038/s41467-024-51960-z.
2
Engineering of a mammalian VMAT2 for cryo-EM analysis results in non-canonical protein folding.工程化哺乳动物 VMAT2 用于冷冻电镜分析导致非典型蛋白折叠。
Nat Commun. 2024 Aug 2;15(1):6511. doi: 10.1038/s41467-024-50934-5.
3
Structural snapshots of human VMAT2 reveal insights into substrate recognition and proton coupling mechanism.人类囊泡单胺转运体2(VMAT2)的结构快照揭示了底物识别和质子偶联机制的相关见解。
Cell Res. 2024 Aug;34(8):586-589. doi: 10.1038/s41422-024-00974-9. Epub 2024 May 22.
4
Structural mechanisms for VMAT2 inhibition by tetrabenazine.四苯嗪抑制 VMAT2 的结构机制。
Elife. 2024 Mar 22;12:RP91973. doi: 10.7554/eLife.91973.
5
Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines.VMAT2 介导的单胺类突触囊泡摄取的转运和抑制机制。
Cell Res. 2024 Jan;34(1):47-57. doi: 10.1038/s41422-023-00906-z. Epub 2024 Jan 2.
6
Transport and inhibition mechanisms of human VMAT2.人 VMAT2 的转运和抑制机制。
Nature. 2024 Feb;626(7998):427-434. doi: 10.1038/s41586-023-06926-4. Epub 2023 Dec 11.
7
Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2.人 VMAT2 中神经递质转运和药物抑制的机制。
Nature. 2023 Nov;623(7989):1086-1092. doi: 10.1038/s41586-023-06727-9. Epub 2023 Nov 1.
8
Cryo-EM structures of human organic anion transporting polypeptide OATP1B1.人有机阴离子转运多肽 OATP1B1 的冷冻电镜结构。
Cell Res. 2023 Dec;33(12):940-951. doi: 10.1038/s41422-023-00870-8. Epub 2023 Sep 6.
9
Molecular mechanism of substrate recognition by folate transporter SLC19A1.叶酸转运蛋白SLC19A1识别底物的分子机制。
Cell Discov. 2022 Dec 28;8(1):141. doi: 10.1038/s41421-022-00508-w.
10
Cryo-EM structure of the human sodium-chloride cotransporter NCC.人氯化钠协同转运蛋白NCC的冷冻电镜结构
Sci Adv. 2022 Nov 11;8(45):eadd7176. doi: 10.1126/sciadv.add7176. Epub 2022 Nov 9.